Jardiance (Empagliflozin) Safety for Young Adults Ages 18 to 29

What Is Empagliflozin and Why Are Young Adults Prescribed It?

Empagliflozin belongs to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class. It blocks glucose reabsorption in the proximal renal tubule, forcing roughly 70 grams of glucose into the urine each day, which lowers blood glucose without stimulating insulin release [1]. The FDA first approved it in August 2014 for type 2 diabetes, then expanded indications to include heart failure with reduced ejection fraction (HFrEF) in 2021 and chronic kidney disease (CKD) in 2023 [2].

Why Young Adults Are Increasingly on This Drug

Type 2 diabetes in people aged 18 to 29 is rising sharply. CDC surveillance data show that incidence of diagnosed type 2 diabetes in adults under 30 increased by roughly 4.8% per year between 2002 and 2018 [3]. That trend means more young adults now meet criteria for an SGLT2 inhibitor, either for glycemic control or for the cardiorenal benefits established in large outcome trials.

How the Mechanism Affects Safety in This Age Group

Because the glucose-lowering effect depends on kidney filtration, young adults with normal renal function (eGFR typically above 90 mL/min/1.73 m²) experience the drug's full pharmacodynamic effect. That is a double-edged point: better glycosuria means stronger glucose lowering, but it also means higher urine glucose concentrations, which feeds the organisms responsible for genital mycotic infections [4].

Cardiovascular Safety: What the Evidence Shows

The landmark EMPA-REG OUTCOME trial (N=7,020 adults with T2D and established cardiovascular disease) showed empagliflozin reduced cardiovascular death by 38% compared with placebo (hazard ratio 0.62; 95% CI 0.49 to 0.77; P<0.001) and reduced hospitalization for heart failure by 35% [5]. The FDA now recognizes these benefits in its approved labeling.

Age-Specific Cardiovascular Data

EMPA-REG OUTCOME enrolled participants with a mean age of 63 years. No pre-specified subgroup analysis isolated adults under 30 [5]. That gap matters. Younger adults with T2D generally carry lower baseline cardiovascular event rates, so the absolute risk reduction from empagliflozin will be smaller even if relative risk reduction is similar. A 2022 sub-analysis published in the Journal of the American College of Cardiology confirmed that SGLT2 inhibitor benefit scales with baseline cardiovascular risk, meaning young adults with no established CVD gain proportionally less near-term cardiovascular protection [6].

Blood Pressure Effects

Empagliflozin lowers systolic blood pressure by approximately 3 to 5 mmHg through osmotic diuresis. In young adults, who often have lower baseline blood pressure than older patients, this reduction could cause symptomatic hypotension, particularly in those who are volume-depleted or physically active [7]. Clinicians should check sitting and standing blood pressure at initiation and after any dose increase.

Genital Mycotic Infections: The Most Common Side Effect in This Age Group

Genital mycotic infections are the most frequently reported adverse effect of empagliflozin and all SGLT2 inhibitors [8]. Pooled safety data from phase 3 empagliflozin trials show a rate of 5.4% in women and 1.5% in men taking the drug versus 0.3% and 0.4%, respectively, on placebo [9].

Why Young Adults Are Particularly Susceptible

Young adults, especially women, already have a higher background rate of vulvovaginal candidiasis compared with older postmenopausal women who lack estrogen-driven vaginal glycogen. Adding glucosuria on top of a baseline-susceptible microbiome raises the probability of recurrent infection meaningfully. In one pooled analysis of three empagliflozin trials, women under 45 showed higher absolute rates of genital infection than older women [9].

Management Strategies

Most infections resolve with a standard course of topical or oral antifungal therapy and do not require stopping empagliflozin. The prescribing label recommends patients maintain good genital hygiene and report persistent or recurrent symptoms [2]. Recurrence rates for women staying on the drug run approximately 20% over 12 months, based on pooled phase 3 data [9]. If a patient has three or more episodes within six months, switching to a different drug class is reasonable.

Diabetic Ketoacidosis Risk: Low but Real

Euglycemic DKA is a rare but serious adverse effect of SGLT2 inhibitors. The term "euglycemic" means blood glucose may be only mildly elevated (often below 250 mg/dL), making the diagnosis easy to miss [10]. The FDA issued a safety communication in 2015 warning about this risk, and the current Jardiance label carries a black-box-adjacent warning instructing clinicians to assess for ketoacidosis in any patient presenting with nausea, vomiting, abdominal pain, or malaise [2].

Estimated Incidence

Across the T2D indication, DKA incidence on empagliflozin approximates 0.1% per patient-year in randomized controlled trial settings [10]. Real-world pharmacovigilance data from the FDA Adverse Event Reporting System suggest rates may be higher off-protocol, particularly when patients fast, undergo surgery, or engage in prolonged intense exercise without dose-holding [11].

Specific Risks for Young Active Adults

Young adults in the 18 to 29 range are more likely to fast intermittently, train athletically, or drink alcohol, all of which can precipitate DKA by suppressing insulin secretion and increasing ketone production. The 2020 American Diabetes Association Standards of Medical Care state that patients should hold empagliflozin at least 24 hours before any elective surgical procedure [12]. Clinicians prescribing to young active patients should provide explicit instructions about holding the drug before sustained fasting, endurance events lasting more than two hours, or any acute illness that limits oral intake.

Fertility, Pregnancy, and Contraception Considerations

No randomized controlled trials of empagliflozin have been conducted in pregnant humans. The FDA label classifies empagliflozin as a drug that should be discontinued when pregnancy is detected, specifically before the second trimester, because animal studies at doses producing systemic exposures approximately 4-fold above the human 25 mg dose showed fetal kidney toxicity during the period of nephrogenesis [2].

Animal Reproductive Toxicology

In rat studies, empagliflozin caused dose-dependent increases in renal pelvis dilation in offspring when administered during the equivalent of the second and third trimesters [2]. Nephrogenesis in humans continues through approximately 36 weeks gestation, which is why the label advises stopping the drug no later than the point of confirmed pregnancy, ideally before conception if pregnancy is planned.

Fertility in Men and Women

The current prescribing information states that animal fertility studies at clinical doses showed no adverse effects on male or female fertility [2]. No published human fertility trials exist for empagliflozin specifically. Young adults planning pregnancy should discuss timing of discontinuation with their prescriber. Women of childbearing potential should use reliable contraception while on the drug and have a pregnancy test before starting.

Lactation

Empagliflozin is present in rodent milk. Because the drug may affect renal development in nursing infants and because human lactation data are absent, the label advises against use while breastfeeding [2]. This consideration is particularly relevant for young adult women who may be postpartum and wish to resume therapy.

Urinary Tract Infections: Separating Signal from Noise

Early regulatory concern existed about urinary tract infection (UTI) risk with SGLT2 inhibitors. For empagliflozin, the data are more reassuring than for some class members. In EMPA-REG OUTCOME, UTI rates were 8.0% in the empagliflozin group versus 7.7% in the placebo group, a difference that was not statistically significant [5]. A 2019 Cochrane review of SGLT2 inhibitors confirmed that empagliflozin showed the least UTI signal among approved agents in its class [13].

Pyelonephritis and Urosepsis

Serious upper UTI, including pyelonephritis and urosepsis, has been reported across the SGLT2 class. The FDA label for empagliflozin includes a warning and advises stopping the drug and initiating antibiotics promptly if a serious UTI develops [2]. Young adults should be instructed to report any fever, flank pain, or rigors immediately.

Renal Safety and Volume Effects

Empagliflozin causes an initial, reversible decline in eGFR of roughly 3 to 5 mL/min/1.73 m² at treatment initiation due to reduced intraglomerular pressure, which actually reflects the drug's renoprotective mechanism rather than harm [14]. In the EMPA-KIDNEY trial (N=6,609 patients with CKD), empagliflozin reduced the composite of kidney disease progression or cardiovascular death by 28% versus placebo (hazard ratio 0.72; 95% CI 0.64 to 0.82; P<0.001) [14].

eGFR Thresholds for Young Adults

Young adults with T2D and preserved renal function can start empagliflozin at eGFR above 30 mL/min/1.73 m². The glycosuric, glucose-lowering effect diminishes substantially at eGFR values below 45 mL/min/1.73 m², though the cardiorenal protective effect persists at lower eGFR levels based on EMPA-KIDNEY data [14]. Starting eGFR and electrolytes should be checked before initiation, then rechecked at 3 months and annually thereafter.

Dehydration Risk in Young Athletes

The osmotic diuretic effect of empagliflozin can cause a 200 to 400 mL per day increase in urine volume. Young adults who exercise heavily in warm weather or who restrict fluid intake for weight class sports face clinically meaningful dehydration risk. Clinicians should counsel patients to increase fluid intake proportionally and to hold the drug during prolonged heat exposure or illness with vomiting.

Drug Interactions Relevant to Young Adults

Several interactions deserve attention in the 18 to 29 population specifically.

Insulin and Sulfonylureas

Combining empagliflozin with insulin or a sulfonylurea increases hypoglycemia risk. If a young adult patient with T2D is on a basal-bolus insulin regimen and empagliflozin is added, insulin doses typically need reduction by 10 to 20% to prevent hypoglycemia [12]. The ADA Standards of Care recommend close glucose monitoring during the first four weeks of combined therapy [12].

Diuretics and Antihypertensives

Young adults on loop diuretics or thiazides for hypertension or heart failure face additive volume depletion when empagliflozin is added. Blood pressure should be rechecked within two weeks of starting the drug in any patient already on a diuretic [7].

NSAIDs and Nephrotoxins

Non-steroidal anti-inflammatory drugs (NSAIDs), commonly used by young adults for sports injuries, reduce renal prostaglandin synthesis and can impair the same intraglomerular pressure pathway that empagliflozin relies on. Concurrent use raises acute kidney injury risk and should be minimized [7].

Dosing Protocol for Adults 18 to 29

The standard starting dose is 10 mg orally once daily, taken in the morning with or without food. For improved glycemic control in T2D, the dose may be increased to 25 mg once daily after at least four weeks at 10 mg, provided eGFR remains above 45 mL/min/1.73 m² [2]. For heart failure or CKD indications, 10 mg once daily is the target dose and no up-titration is needed or recommended.

Dose adjustments are not required based on age alone within the adult 18-and-older range. Body weight also does not require dose adjustment, though pharmacokinetic data show that plasma exposure is approximately 20% higher in patients with lower body weight, which could subtly amplify both benefit and side-effect risk in lean young adults [2].

Monitoring Schedule Recommended by Guidelines

The 2024 ADA Standards of Medical Care recommend the following monitoring cadence for patients on SGLT2 inhibitors [12]:

• Before starting: eGFR, serum electrolytes, blood pressure, urine albumin-to-creatinine ratio, pregnancy test in women of childbearing potential.
• At 3 months: eGFR recheck, blood pressure, HbA1c, symptom review for genital infection or UTI.
• Annually: eGFR, HbA1c, urine albumin-to-creatinine ratio, liver function tests, lipid panel.
• Any acute illness: Hold drug and reassess within 48 to 72 hours.

The ADA notes that "SGLT2 inhibitors have demonstrated benefits in reducing cardiovascular and kidney outcomes independent of glucose lowering, and their use should be considered in all patients with type 2 diabetes and established CVD, high CV risk, CKD, or heart failure" [12].

How Empagliflozin Fits Into Lifestyle Patterns Common at Ages 18 to 29

Young adults face specific lifestyle-related challenges that older clinical trial populations do not. Alcohol consumption, intermittent fasting, high-intensity training, and inconsistent meal timing are all common at this life stage and all interact with empagliflozin's mechanism.

Alcohol

Alcohol suppresses hepatic gluconeogenesis and increases ketone production. When combined with empagliflozin, which itself promotes ketogenesis through reduced insulin levels and increased glucagon-to-insulin ratio, even moderate alcohol intake may raise the risk of euglycemic DKA meaningfully. Patients should be counseled to eat a carbohydrate-containing meal whenever they drink and to limit intake to moderate amounts (two standard drinks or fewer per occasion) [10].

Intermittent Fasting

Periods of fasting longer than 12 hours should prompt patients to consider holding empagliflozin for that day, particularly during extended (greater than 24-hour) fasting protocols. No published RCT has evaluated empagliflozin specifically in intermittent fasting regimens for young adults with T2D. The ADA advises caution with SGLT2 inhibitor use during calorie-restriction periods [12].

Exercise and Sports

Physical activity is encouraged and enhances empagliflozin's glucose-lowering effect by increasing peripheral glucose uptake independently. A 2021 meta-analysis of 12 trials (N=2,344 patients) found that SGLT2 inhibitors combined with structured exercise reduced HbA1c by an additional 0.4% compared with exercise alone [15]. Young adults should be instructed, though, to maintain adequate hydration and to consume at least 30 to 45 grams of carbohydrate before exercise sessions lasting more than 60 minutes.

What Clinicians and Young Patients Should Discuss Before Starting

A shared decision-making conversation before prescribing empagliflozin to a patient aged 18 to 29 should cover at minimum the following points, drawn from FDA label guidance and ADA Standards [2, 12]:

1. The drug's primary mechanism (glucosuria) and why it differs from insulin-based therapies.
2. Genital mycotic infection risk, hygiene strategies, and the threshold for reporting symptoms.
3. DKA warning signs and the importance of holding the drug before fasting, surgery, or prolonged exercise.
4. Pregnancy avoidance or the plan to stop the drug before the second trimester.
5. Volume depletion signs (dizziness, thirst, reduced urine output) and when to call the clinic.
6. The interaction between alcohol and ketone production.

The Endocrine Society's 2023 clinical practice guideline on pharmacotherapy for type 2 diabetes states: "For adults with type 2 diabetes and high cardiovascular or renal risk, an SGLT2 inhibitor with proven cardiovascular benefit should be recommended as a preferred add-on to metformin regardless of HbA1c, with individualized discussion of side-effect profiles" [16].